Last $5.53 USD
Change Today -0.29 / -4.98%
Volume 173.2K
NBS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Andrew L. Pecora M.D., F.A.C.P.

Chief Visionary Officer, Director, Chief Scientific Officer of Amorcyte Inc and Chief Medical Officer of Progenitor Cell Therapy Llc , Neostem, Inc.
AgeTotal Calculated CompensationThis person is connected to 54 board members in 4 different organizations across 7 different industries.

See Board Relationships
57$873,014
As of Fiscal Year 2013

Background*

Dr. Andrew L. Pecora, M.D., F.A.C.P., has been the Chief Visionary Officer of Neostem, Inc., since August 5, 2013. Dr. Pecora founded Amorcyte, LLC in 2005 and serves as its Chief Scientific Officer. He is the Founder and Executive Chairman of Cota. He serves as the Chairman of Cancer Center Department at Hackensack University Medical Center. He served as the Chief Medical Officer of Progenitor Cell Therapy, LLC , a wholly-owned Subsidiary of Neostem, Inc. since January ...

Read Full Background

Corporate Headquarters*

420 Lexington Avenue
New York, New York 10170

United States

Phone: 212-584-4180
Fax: 646-514-7787

Board Members Memberships*

Former Chairman of the Board, Chief Executive Officer, Chief Medical Officer and Member of Board Manager
Founder and Chief Scientific Officer
Chairman
Founder and Executive Chairman
2004-2014
Former Director
2007-Present
Chairman
2011-Present
Chief Visionary Officer, Director, Chief Scientific Officer of Amorcyte Inc and Chief Medical Officer of Progenitor Cell Therapy Llc

Education*

Bachelor's Degree
University of Medicine and Dentistry of New Jersey
BS
Seton Hall University

Other Affiliations*

Annual Compensation*

Salary$221,538
Bonus$365,004
Total Annual Compensation$586,542

Stock Options*

Exercisable Options112,793
Unexercisable Options66,207
Total Number of Options179,000

Total Compensation*

Total Annual Cash Compensation$586,542
Total Short Term Compensation$586,542
Total Calculated Compensation$873,014
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBS:US $5.53 USD -0.29

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Gil Van Bokkelen Ph.D.Co-Founder, Chairman and Chief Executive Officer
Athersys, Inc.
$568.8K
Michael D. West Ph.D.Chief Executive Officer, President and Director
BioTime, Inc.
$745.3K
Marc H. Hedrick M.D.Chief Executive Officer, President, Director and Member of Executive Committee
Cytori Therapeutics, Inc.
$406.6K
Paul K. Wotton Ph.D.Chief Executive Officer, President, Director and Member of Pricing Committee
Advanced Cell Technology Inc.
--
Zami Aberman Executive Chairman and Chief Executive Officer
Pluristem Therapeutics, Inc.
$503.7K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOSTEM INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.